A panel that advises the Food and Drug Administration agreed that a new drug to treat Alzheimer’s disease was beneficial for slowing cognitive decline, paving the way for full regulatory approval next month.
Earlier this year, the drug, known as lecanemab, was granted partial, or accelerated, approval, but that restricted it to people who could pay $26,500 a year or were…